Abstract
The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Current Drug Targets
Title: New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets
Volume: 9 Issue: 5
Author(s): Tommaso Stefanelli, Alberto Malesci, Alessandro Repici, Stefania Vetrano and Silvio Danese
Affiliation:
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Abstract: The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Export Options
About this article
Cite this article as:
Stefanelli Tommaso, Malesci Alberto, Repici Alessandro, Vetrano Stefania and Danese Silvio, New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221170
DOI https://dx.doi.org/10.2174/138945008784221170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Current Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Systems Biology of HBOC-Induced Vasoconstriction
Current Drug Discovery Technologies Microbial Agents – Parasites
Current Rheumatology Reviews Subject Index To Volume 2
Current Rheumatology Reviews Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Association of Large Vessel Aneurysm/Pseudo-Aneurysm/Aortitis and Deep Vein Thrombosis in Patients with Behçet’s Disease: A Case Report
Current Rheumatology Reviews Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin
Current Signal Transduction Therapy Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Mechanisms of Drug Hypersensitivity Reactions and the Skin
Recent Patents on Inflammation & Allergy Drug Discovery Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research TNF-induced Lupus. A Case-Based Review
Current Rheumatology Reviews Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets